Menu
Apply

Mucopolysaccharidosis VII

Co-Pay Relief Program Fund Notices

Would you like to be notified when any new funds open, or when any of our current funds re-open? If so, please sign up using the “Get Notified” link below. As a member of our subscriber community you will receive important news about all of our disease funds, so join today!

Get Notified


Status
Identified

Approved and Donation Ready

This fund has been developed in response to patients who have contacted PAF for help with their medication expenses and could not find help. While this fund has been fully designed and we are ready to provide needed support to these patient communities, this fund is not yet able to accept applications for assistance as we are still working to secure charitable donations that will allow us to open it.

If you, or someone you know, would like to contribute to this fund, please visit our Donors page for more information on how to provide critical support for patients in need.

Fund Type

Co-Pay, Co-insurance & Deductible (medications and office visits)

Maximum Award Level

$12,500

Eligibility Requirements
  • Household Income Requirements 400% or less of Federal Poverty Guideline (FPG) (adjusted for Cost of Living Index (COLI) and number in household)
  • Insurance Requirements All Insurance Types
  • Must reside and receive treatment in the United States.

About Mucopolysaccharidosis VII

Mucopolysaccharidosis type VII (MPS VII), also known as Sly syndrome, is a progressive condition that affects most tissues and organs. The severity of MPS VII varies widely among affected individuals. The most severe cases of MPS VII are characterized by hydrops fetalis, a condition in which excess fluid builds up in the body before birth. Most babies with hydrops fetalis are stillborn or die soon after birth. Other people with MPS VII typically begin to show signs and symptoms of the condition during early childhood. The features of MPS VII include a large head , a buildup of fluid in the brain, distinctive-looking facial features that are described as “”coarse,”” and a large tongue. Affected individuals also frequently develop an enlarged liver and spleen, heart valve abnormalities, and umbilical hernia or lower abdomen hernia. The airway may become narrow in some people with MPS VII, leading to frequent upper respiratory infections and sleep apnea. The eye’s cornea becomes cloudy, which can cause significant vision loss. People with MPS VII may also have recurrent ear infections and hearing loss. Affected individuals may have developmental delay and progressive intellectual disability, although intelligence is unaffected in some people with this condition.  MPS VII is estimated to occur in 1 in 250,000 newborns. It is one of the rarest types of mucopolysaccharidosis. MPS VII causes various skeletal abnormalities that become more pronounced with age, including short stature and joint deformities (contractures) that affect mobility. Other names for this condition include: beta-glucuronidase deficiency, GUSB deficiency, MPS VII, Mucopolysaccharidosis 7, and Sly Syndrome.

Mucopolysaccharidosis VII Resources
Medication & Financial Assistance Resources
The Patient Advocate Foundation's (PAF) Co-Pay Relief (CPR) Program does not review the information contained on the website links provided for content, accuracy or completeness. Use of and access to this information is subject to the terms, limitations and conditions as outlined on the accessed websites. PAF Co-Pay Relief Program makes no representation as to the accuracy or any other aspect of the information contained on any website accessed from the CPR website, nor does PAF Co-Pay Relief Program necessarily endorse the website information provided. The information presented on the PAF Co-Pay Relief website is provided for general information only and is not intended as a substitute for medical care. Please talk with your healthcare provider about any information you acquire from this or any other website accessed through the PAF Co-Pay Relief program website.
Apply